Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01248195




Registration number
NCT01248195
Ethics application status
Date submitted
20/10/2010
Date registered
25/11/2010
Date last updated
15/05/2018

Titles & IDs
Public title
Optimization of Treatment and Management of Schizophrenia in Europe
Scientific title
Optimization of Treatment and Management of Schizophrenia in Europe
Secondary ID [1] 0 0
2010-020185-19
Secondary ID [2] 0 0
KP7242114
Universal Trial Number (UTN)
Trial acronym
OPTIMISE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Schizophrenia 0 0
Schizophreniform Disorder 0 0
Schizoaffective Disorder 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Schizophrenia
Mental Health 0 0 0 0
Psychosis and personality disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Amisulpride open label
Treatment: Drugs - 6-week amisulpride double blind treatment
Treatment: Drugs - 6-week olanzapine double blind treatment
Treatment: Drugs - 12-week clozapine open-label treatment
BEHAVIORAL - Psychosocial intervention

Other: Phase I: 1 arm 'amisulpride open label' - For 4 weeks, all patients will be treated with amisulpride open label.

Active comparator: Phase II: 'amisulpride double blind' - Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'

Active comparator: Phase II 'olanzapine double blind' - Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'

Other: Phase III: 1 arm 'clozapine open label' - Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'

Experimental: Psychosocial intervention - Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.

No intervention: Psychosocial Intervention phase: 'TAU' - Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.


Treatment: Drugs: Amisulpride open label
4-week open label amisulpride treatment

Treatment: Drugs: 6-week amisulpride double blind treatment
6-week amisulpride double blind treatment

Treatment: Drugs: 6-week olanzapine double blind treatment
6-week olanzapine double blind treatment

Treatment: Drugs: 12-week clozapine open-label treatment
12-week clozapine open-label treatment

BEHAVIORAL: Psychosocial intervention
Psychosocial intervention
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
BEHAVIORAL
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
PANSS
Timepoint [1] 0 0
Jan 2016
Primary outcome [2] 0 0
Sellwood rating scale
Timepoint [2] 0 0
Jan 2016
Primary outcome [3] 0 0
Biological profile
Timepoint [3] 0 0
jan 2016
Primary outcome [4] 0 0
MRS measures
Timepoint [4] 0 0
jan 2016
Primary outcome [5] 0 0
SOFAS global functioning
Timepoint [5] 0 0
jan 2016
Primary outcome [6] 0 0
MRI assessments
Timepoint [6] 0 0
jan 2016
Secondary outcome [1] 0 0
All cause treatment discontinuation
Timepoint [1] 0 0
jan 2016
Secondary outcome [2] 0 0
All cause discontinuation
Timepoint [2] 0 0
jan 2016
Secondary outcome [3] 0 0
Biological markers
Timepoint [3] 0 0
jan 2016
Secondary outcome [4] 0 0
MRI assessments
Timepoint [4] 0 0
jan 2016

Eligibility
Key inclusion criteria
1. Diagnosis of schizophrenia as defined by DSM-IV-R as determined by the M.I.N.I.plus
2. Age 18 or older.
3. The first psychosis occurred at least one year and no more than 7 years ago.*
4. If patients are using an antipsychotic drug, a medication switch is currently under consideration.
5. Capable of providing written informed consent.
Minimum age
18 Years
Maximum age
40 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Intolerance / hypersensitivity to one of the drugs (including active substances, metabolites and excipients) in this study including oral risperidone, paliperidone and aripiprazole and/or hypersensitivity to risperidone.
2. Pregnancy or lactation.
3. Patients who are currently using clozapine.
4. Patients who do not fully comprehend the purpose or are not competent to make a rational decision whether or not to participate.
5. Patients with a documented history of non-response and/or intolerance to any of the study medications and/or a documented history of non-response to a treatment with one of the study drugs of at least 6 weeks within the registered dose range.
6. Forensic patients.
7. Patients who have been treated with an investigational drug within 30 days prior to screening.
8. Simultaneous participation in another intervention study (neither medication or psychosocial intervention).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2016
Sample size
Target
Accrual to date
Final
479
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Melbourne Neuropsychiatry Centre - Melbourne
Recruitment postcode(s) [1] 0 0
3053 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Innsbruck
Country [2] 0 0
Belgium
State/province [2] 0 0
Leuven
Country [3] 0 0
Bulgaria
State/province [3] 0 0
Sofia
Country [4] 0 0
Czechia
State/province [4] 0 0
Ustavni 91
Country [5] 0 0
Czechia
State/province [5] 0 0
Hradec Králové
Country [6] 0 0
Denmark
State/province [6] 0 0
Glostrup
Country [7] 0 0
France
State/province [7] 0 0
Créteil Cedex
Country [8] 0 0
Germany
State/province [8] 0 0
Halle
Country [9] 0 0
Germany
State/province [9] 0 0
Mannheim
Country [10] 0 0
Germany
State/province [10] 0 0
München
Country [11] 0 0
Israel
State/province [11] 0 0
Tel Hashomer
Country [12] 0 0
Italy
State/province [12] 0 0
Naples
Country [13] 0 0
Netherlands
State/province [13] 0 0
Utrecht
Country [14] 0 0
Poland
State/province [14] 0 0
Poznan
Country [15] 0 0
Romania
State/province [15] 0 0
Bucuresti
Country [16] 0 0
Spain
State/province [16] 0 0
Barcelona
Country [17] 0 0
Spain
State/province [17] 0 0
Madrid
Country [18] 0 0
Spain
State/province [18] 0 0
Oviedo
Country [19] 0 0
Switzerland
State/province [19] 0 0
Oetwil am See
Country [20] 0 0
United Kingdom
State/province [20] 0 0
London
Country [21] 0 0
United Kingdom
State/province [21] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Other
Name
Rene Kahn
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
King's College London
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Technical University of Munich
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
University of Manchester
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Ludwig-Maximilians - University of Munich
Address [4] 0 0
Country [4] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development.
Trial website
https://clinicaltrials.gov/study/NCT01248195
Trial related presentations / publications
Fraguas D, Diaz-Caneja CM, Pina-Camacho L, Winter van Rossum I, Baandrup L, Sommer IE, Glenthoj B, Kahn RS, Leucht S, Arango C. The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study. Schizophr Res. 2021 May;231:100-107. doi: 10.1016/j.schres.2021.03.010. Epub 2021 Apr 7.
Pollak TA, Vincent A, Iyegbe C, Coutinho E, Jacobson L, Rujescu D, Stone J, Jezequel J, Rogemond V, Jamain S, Groc L, David A, Egerton A, Kahn RS, Honnorat J, Dazzan P, Leboyer M, McGuire P. Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biol Psychiatry. 2021 Jul 1;90(1):9-15. doi: 10.1016/j.biopsych.2020.11.014. Epub 2020 Nov 24. Erratum In: Biol Psychiatry. 2021 Jul 1;90(1):69. doi: 10.1016/j.biopsych.2021.04.001.
Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Diaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthoj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE; OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018 Oct;5(10):797-807. doi: 10.1016/S2215-0366(18)30252-9. Epub 2018 Aug 13.
Public notes

Contacts
Principal investigator
Name 0 0
René Kahn, MD, PhD
Address 0 0
University Medical Center Utrecht, the Netherlands
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01248195